Evidence map›Paper›PMID 28775680›Full record

ArticleFrontiers in cellular neuroscience2017

Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients.

Deepali Mathur, Angela L Riffo-Campos, Josefa Castillo, Jeffery D Haines, Oscar G Vidaurre, Fan Zhang, Francisco Coret-Ferrer, Patrizia Casaccia, Bonaventura Casanova, Gerardo Lopez-Rodas

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Complex II ambiguities-FADHThe Journal of biological chemistry · 2024
    Review
  3. Review
  4. Potential Biomarkers Associated with Multiple Sclerosis Pathology.International journal of molecular sciences · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Deepali MathurDepartment of Functional Biology, University of ValenciaValencia, Spain.
Angela L Riffo-CamposDepartment of Biochemistry and Molecular Biology, INCLIVA Biomedical Research Institute, University of ValenciaValencia, Spain.
Josefa CastilloDepartment of Biochemistry and Molecular Biology, INCLIVA Biomedical Research Institute, University of ValenciaValencia, Spain.
Jeffery D HainesDepartment of Neuroscience, Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New YorkNY, United States.
Oscar G VidaurreDepartment of Neuroscience, Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New YorkNY, United States.
Fan ZhangDepartment of Neuroscience, Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New YorkNY, United States.
Francisco Coret-FerrerHospital Clínico Universitario de ValenciaValencia, Spain.
Patrizia CasacciaDepartment of Neuroscience, Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New YorkNY, United States.
Bonaventura CasanovaCSUR-Esclerosi Múltiple, Unitat Mixta d'Esclerosi Múltiple i Neurorregeneració del'IIS-La Fe, Hospital Universitari i Politécnic La FeValencia, Spain.
Gerardo Lopez-RodasDepartment of Biochemistry and Molecular Biology, INCLIVA Biomedical Research Institute, University of ValenciaValencia, Spain.
Icahn School of Medicine at Mount Sinai · USUniversitat de València · ESHospital Clínico Universitario de Valencia · ESHospital Universitari i Politècnic La Fe · ESUniversidad de La Frontera · CL

Funding

Histone Deacetylation in Oligodendrocyte DifferentiationR37NS042925 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CASACCIA, PATRIZIA · 2012 to 2018
$4.3M
NINDS NIH HHS R37 NS042925
6 · The paper itself

Abstract

In relapsing-remitting multiple sclerosis (RRMS) subtype, the patient's brain itself is capable of repairing the damage, remyelinating the axon and recovering the neurological function. Cerebrospinal fluid (CSF) is in close proximity with brain parenchyma and contains a host of proteins and other molecules, which influence the cellular physiology, that may balance damage and repair of neurons and glial cells. The purpose of this study was to determine the pathophysiological mechanisms underpinning myelin repair in distinct clinical forms of MS and neuromyelitis optica (NMO) patients by studying the effect of diseased CSF on glucose metabolism and ATP synthesis. A cellular model with primary cultures of oligodendrocyte progenitor cells (OPCs) from rat cerebrum was employed, and cells were treated with CSF from distinct clinical forms of MS, NMO patients and neurological controls. Prior to comprehending mechanisms underlying myelin repair, we determine the best stably expressed reference genes in our experimental condition to accurately normalize our target mRNA transcripts. The

Indexed as

cerebrospinal fluidgene expressionglucose metabolismmultiple sclerosismyelin repairneuromyelitis opticaoligodendrocyte progenitor cells

Identifiers

PMID28775680
PMCPMC5517784
OpenAlexW2737874465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.